CA2439630A1 - Use of biomolecular targets in the treatment and visualization of brain tumors - Google Patents

Use of biomolecular targets in the treatment and visualization of brain tumors Download PDF

Info

Publication number
CA2439630A1
CA2439630A1 CA002439630A CA2439630A CA2439630A1 CA 2439630 A1 CA2439630 A1 CA 2439630A1 CA 002439630 A CA002439630 A CA 002439630A CA 2439630 A CA2439630 A CA 2439630A CA 2439630 A1 CA2439630 A1 CA 2439630A1
Authority
CA
Canada
Prior art keywords
ser
leu
glu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439630A
Other languages
English (en)
French (fr)
Inventor
Sabine Mueller
Thorsten Melcher
Daniel J. Chin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGY Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/816,703 external-priority patent/US6455026B1/en
Priority claimed from US09/983,000 external-priority patent/US20030118585A1/en
Application filed by Individual filed Critical Individual
Publication of CA2439630A1 publication Critical patent/CA2439630A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002439630A 2001-03-23 2002-03-22 Use of biomolecular targets in the treatment and visualization of brain tumors Abandoned CA2439630A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/816,703 2001-03-23
US09/816,703 US6455026B1 (en) 2001-03-23 2001-03-23 Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US09/983,000 2001-10-17
US09/983,000 US20030118585A1 (en) 2001-10-17 2001-10-17 Use of protein biomolecular targets in the treatment and visualization of brain tumors
PCT/US2002/008992 WO2002076510A1 (en) 2001-03-23 2002-03-22 Use of biomolecular targets in the treatment and visualization of brain tumors

Publications (1)

Publication Number Publication Date
CA2439630A1 true CA2439630A1 (en) 2002-10-03

Family

ID=27124105

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439630A Abandoned CA2439630A1 (en) 2001-03-23 2002-03-22 Use of biomolecular targets in the treatment and visualization of brain tumors

Country Status (4)

Country Link
EP (1) EP1383543A4 (cg-RX-API-DMAC10.html)
JP (1) JP2004537282A (cg-RX-API-DMAC10.html)
CA (1) CA2439630A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002076510A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303244A (zh) * 2013-11-04 2020-06-19 伊玛提克斯生物技术有限公司 几种神经元和脑肿瘤的个性化免疫疗法
CN121249676A (zh) * 2025-12-05 2026-01-02 重庆医科大学附属第一医院 一种met二聚体靶向的放射性核素探针及其制备方法与应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7678769B2 (en) * 2001-09-14 2010-03-16 Compugen, Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
WO2007036945A2 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
WO2005014022A1 (en) 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2006029462A1 (en) * 2004-09-14 2006-03-23 Autogen Research Pty Ltd A nucleic acid molecule differentially expressed in a mouse behavioural model system and uses thereof
ES2828739T3 (es) * 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
WO2009007934A2 (en) 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323884D0 (en) * 1993-11-19 1994-01-05 Eisai London Res Lab Ltd Physiological modulation
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303244A (zh) * 2013-11-04 2020-06-19 伊玛提克斯生物技术有限公司 几种神经元和脑肿瘤的个性化免疫疗法
CN121249676A (zh) * 2025-12-05 2026-01-02 重庆医科大学附属第一医院 一种met二聚体靶向的放射性核素探针及其制备方法与应用

Also Published As

Publication number Publication date
EP1383543A4 (en) 2006-06-21
JP2004537282A (ja) 2004-12-16
WO2002076510A1 (en) 2002-10-03
EP1383543A1 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
AU2003230807B2 (en) Use of biomolecular targets in the treatment and visualization of brain tumors
US7014838B2 (en) Use of biomolecular targets in the treatment and visualization of brain tumors
US20070025997A1 (en) Use of biomolecular targets in the treatment and visualization of brain tumors
US7060275B2 (en) Use of protein biomolecular targets in the treatment and visualization of brain tumors
JP2009148265A (ja) 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原
TW200540420A (en) Cancer specific gene mh15
KR102534098B1 (ko) 항암제 내성 진단 또는 치료용 조성물
JP2004507254A (ja) 癌の診断および治療
CA2516588A1 (en) Assay for detection of renal cell carcinoma
CA2468651A1 (en) Detection of neurodegenerative diseases
WO2002076510A1 (en) Use of biomolecular targets in the treatment and visualization of brain tumors
US20040224337A1 (en) Use of biomolecular targets in the treatment and visualization of tumors
US7560242B2 (en) Metadherin polypeptides, encoding nucleic acids and methods of use
AU2002257085A1 (en) Use of biomolecular targets in the treatment and visualization of brain tumours
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
ES2310554T3 (es) Procedimientos de tratamiento que usan 17906 y usos para el mismo.
KR101483335B1 (ko) 골 손실 진단 마커로서의 피브리노겐의 용도
WO2003066639A2 (en) Methods for identifying targeting domains and methods and compositions comprising the same
CN121249676B (zh) 一种met二聚体靶向的放射性核素探针及其制备方法与应用
Chang et al. Biology of PSMA as a diagnostic and therapeutic target
US20060110395A1 (en) Use of CRKD as a breast cancer marker and cancer therapy target
US20100202964A1 (en) Organ Homing Genes of Cancer Metastases
US20150355185A1 (en) Using galectin-binding carbohydrates as predictors of melanoma progression and metastasis
JP2005508618A (ja) 双極性障害に関連する核酸およびコードされるポリペプチド

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead